• Mustafa Kemal Celen, Duygu Mert, Müzeyyen Ay, Tuba Dal, Safak Kaya, Necmettin Yildirim, Serda Gulsun, Tunga Barcin, Sevgi Kalkanli, Mehmet Sinan Dal, and Celal Ayaz.
• Mustafa Kemal Celen, Celal Ayaz, Department of Infectious Diseases, Faculty of Medicine, Dicle University, 21280 Yenişehir, Diyarbakir, Turkey.
• World J. Gastroenterol. 2013 Dec 28; 19 (48): 9377-82.

AimTo evaluate the effects of tenofovir disoproxil fumarate (TDF) use during late pregnancy to reduce hepatitis B virus (HBV) transmission in highly viremic mothers.MethodsThis retrospective study included 45 pregnant patients with hepatitis B e antigen (+) chronic hepatitis B and HBV DNA levels > 10⁷ copies/mL who received TDF 300 mg/d from week 18 to 27 of gestation (n = 21). Untreated pregnant patients served as controls (n = 24). All infants received 200 IU of hepatitis B immune globulin (HBIG) within 24 h postpartum and 20 μg of recombinant HBV vaccine at 4, 8, and 24 wk. Perinatal transmission rate was determined by hepatitis B surface antigen and HBV DNA results in infants at week 28.ResultsAt week 28, none of the infants of TDF-treated mothers had immunoprophylaxis failure, whereas 2 (8.3 %) of the infants of control mothers had immunoprophylaxis failure (P = 0.022). There were no differences between the groups in terms of adverse events in mothers or congenital deformities, gestational age, height, or weight in infants. At postpartum week 28, significantly more TDF-treated mothers had levels of HBV DNA < 250 copies/mL and normalized alanine aminotransferase compared with controls (62% vs none, P < 0.001; 82% vs 61%, P = 0.012, respectively).ConclusionTDF therapy during the second or third trimester reduced perinatal transmission rates of HBV and no adverse events were observed in mothers or infants.

56 keywords...

hide…